Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 146

Showing 1-25 of 146 citing articles:

Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 114
A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐Targeting Chimeras Enhanced Immunotherapy
Yaping Wu, Xiaowei Chang, Guizhu Yang, et al.
Advanced Materials (2023) Vol. 35, Iss. 12
Open Access | Times Cited: 50
Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Weishan Wang, Chenghong Zhu, Bin Zhang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16642-16649
Closed Access | Times Cited: 41
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 27
TRAP1 drives smooth muscle cell senescence and promotes atherosclerosis via HDAC3-primed histone H4 lysine 12 lactylation
Xuesong Li, Minghong Chen, Xiang Chen, et al.
European Heart Journal (2024) Vol. 45, Iss. 39, pp. 4219-4235
Open Access | Times Cited: 25
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22
Macrophage MCT4 inhibition activates reparative genes and protects from atherosclerosis by histone H3 lysine 18 lactylation
Yunjia Zhang, Hong Jiang, Mengdie Dong, et al.
Cell Reports (2024) Vol. 43, Iss. 5, pp. 114180-114180
Open Access | Times Cited: 19
Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, et al.
Nanoscale (2024) Vol. 16, Iss. 9, pp. 4378-4391
Closed Access | Times Cited: 18
PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
Kailee A. Rutherford, Kirk J. McManus
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 4, pp. 454-463
Open Access | Times Cited: 17
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Nicolas Guedeney, Marie Cornu, Florian Schwalen, et al.
Drug Discovery Today (2022) Vol. 28, Iss. 1, pp. 103395-103395
Open Access | Times Cited: 64
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 35
Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins
J. Thomas, Mi Wang, Wei Jiang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8178-8199
Closed Access | Times Cited: 31
Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach
Qiuxia Chen, Chuan Liu, Wei Wang, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 1, pp. 25-33
Open Access | Times Cited: 29
2-Aminobenzothiazoles in anticancer drug design and discovery
G. Huang, Tomasz Cierpicki, Jolanta Grembecka
Bioorganic Chemistry (2023) Vol. 135, pp. 106477-106477
Closed Access | Times Cited: 28
Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy
Ruoxi Sang, Renming Fan, Aohua Deng, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8464-8483
Closed Access | Times Cited: 28
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
Jiarui Hu, Dan Zhang, Keyue Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115475-115475
Closed Access | Times Cited: 27
The rise of degrader drugs
Mingxing Teng, Nathanael S. Gray
Cell chemical biology (2023) Vol. 30, Iss. 8, pp. 864-878
Open Access | Times Cited: 27
Carrier-Free Nano-PROTACs to Amplify Photodynamic Therapy Induced DNA Damage through BRD4 Degradation
Linping Zhao, Xiaona Rao, Rongrong Zheng, et al.
Nano Letters (2023) Vol. 23, Iss. 13, pp. 6193-6201
Closed Access | Times Cited: 26
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 25
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1700-1711
Closed Access | Times Cited: 23
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
Ritesh P. Bhole, Payal R. Kute, Rupesh V. Chikhale, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106720-106720
Closed Access | Times Cited: 23
Recent advances in targeted protein degraders as potential therapeutic agents
Na Yang, Bo Kong, Zhaohong Zhu, et al.
Molecular Diversity (2023) Vol. 28, Iss. 1, pp. 309-333
Open Access | Times Cited: 22
The progress of molecules and strategies for the treatment of HBV infection
Youlu Pan, Heye Xia, Yanwen He, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top